medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Número 2

<< Anterior Siguiente >>

Ann Hepatol 2013; 12 (2)


Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice

Miquel M, Núñez Ó, Trapero-Marugán M, Díaz-Sánchez A, Jiménez M, Arenas J, Canós AP

Idioma: Ingles.
Referencias bibliográficas: 31
Paginas: 205-212
Archivo PDF: 121.82 Kb.


RESUMEN

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.

  2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepatitis 2004; 11: 97-107.

  3. Liaw YF. Prevention and surveillance of hepatitis B virusrelated hepatocellular carcinoma. Semin Liver Dis 2005; 25: 40-7.

  4. Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 2006; 26: 142-52.

  5. Alter MJ. Epidemiology and prevention of Hepatitis B. Semin Liver Dis 2003; 23: 39-46.

  6. Berg T, Benhamou Y, Calleja JL, Levrero M, JohnsonW, Ellis N. A survey of chronic hepatitis B patient management practices in the European Union. J Viral Hepatitis 2010; 17: 624-30.

  7. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, et al. Long-Term Entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-93.

  8. Schiff ER, Lee SS, Chao YC, Yoon SK, Bessone F, Wu SS, Kryczka W, et al. Long-term treatment with Entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastro Hepatol 2011; 9: 274-6.

  9. Gane EJ, Marcellin P, Sievert W, Trinh HN, Shiffman ML, Washington M, Barnes CN, et al. Five years of treatment with Tenofovir DF (TDF) for chronic hepatitis B (CHB) infection in Asian patients is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. Hepatology 2011; 54(Suppl. 1): A1429.

  10. Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 1-36.

  11. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, et al., for the Chronic Hepatitis B Guideline Workshop Party of the Asian-Pacific Association for the Study of the Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-83.

  12. Fontana RJ. Entecavir in decompensated HBV cirrhosis: The future is looking brighter. J Hepatol 2010; 52: 147-9.

  13. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D’Amico G, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.

  14. Child CG, Turcotte JC. Surgery and portal hypertension. Major Probl Clin Surg 1964; 1: 1-85.

  15. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.

  16. Hann HW, Fontana RJ, Wright T, Everson G, Baker A, Schiff ER, Riely C, et al. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus related cirrhosis. Liver Transpl 2003; 9: 49-56.

  17. Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann H, et al. Adefovir dipivoxil for wait-listed and post-liver transplantationpatients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13: 349-60.

  18. Gane EJ, Chan HL, Choudhuri G, Suh DJ, Chutaputti A, Safadi R, Tanwandee T, et al. Treatment of decompensated HBV-cirrhosis: results from 2-years randomized trial with telbivudine or lamivudine. J Hepatol 2010; 52(Suppl. 1): S4.

  19. Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000; 33: 301-7.

  20. Kapoor D, Guptan RC, Wakil SM, Kazim SN, Kaul R, Agarwal SR, Raisuddin S, et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000; 33: 308-12.

  21. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, Leduc R, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 207-10.

  22. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001; 34: 411-6.

  23. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.

  24. Shim JH, Lee HC, Ki KM, Kim Y-S, Chung Y-H, Lee YS, Suh DJ. Efficacy of entecavir in treatment-naïve decompensated cirrhosis. J Hepatol 2010; 52: 176-82.

  25. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, Peng CY, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, openlabel study. Hepatology 2011; 54: 91-100.

  26. Hyun JJ, Seo YS, Yoon E, Kim TH, Kim DJ, Kang HS, Jung ES, et al. Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis. Liver Int 2012; 32: 656-64.

  27. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Wong FS-H, Chang TT, et al. Tenofovir disoproxil fumarate (TDF), Emtricitabine/TDF, and Entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53: 62-72.

  28. D’Amico G, Gasrcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol 2006; 44: 217-31.

  29. Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology 2010; 51: 1445-9.

  30. Fontana RJ, Hann H-WL, Perrillo RP, Vierling JM, Wright T, Rakela J, Anschuetz G, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123: 719-27.

  31. Lange CM, Bojunga J, Hoffmann WP, Wunder K, Mihm U, Zeuzem S, Sarrazi C. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50: 2001-9.




2020     |     www.medigraphic.com